Please assess the completion status of the following clinical trial:

Trial Title: Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria are as follows:~* Age: 16 - 80 years~* Subject is having a clinically indicated endoscopy for suspicious EoE and has been on twice daily (BID) proton pump inhibitor (PPI) for at least 8 weeks OR New diagnosis of EoE as per consensus guidelines. Cases must have symptoms of dysphagia, persistent esophageal eosinophilia (≥ 15 eosinophils in at least one high-power field) after 8 weeks of treatment with a twice daily proton-pump inhibitor, and other competing causes of esophageal eosinophilia excluded.~Exclusion criteria are as follows:~* Medical instability that precludes safely performing upper endoscopy~* Ongoing or recent symptoms of intestinal bleeding (throwing up blood, passing blood in the stool)~* Concomitant eosinophilic gastroenteritis~* Esophageal narrowing or stricturing that will not allow a standard 9 mm upper endoscopy scope to pass~* Cancer in the esophagus, stomach, or intestine~* Previous esophageal surgery~* Esophageal varices (dilated blood vessels in the esophagus)~* Current use of blood thinners like Plavix or Coumadin that are not stopped prior to endoscopy procedures~* Any corticosteroid exposure within the 4 weeks prior to their baseline endoscopic exam. Exclusionary corticosteroid exposure is defined as any swallowed topical steroids for EoE or systemic steroids for any condition within the four weeks prior to the baseline endoscopy. Corticosteroids used for asthma or intranasal corticosteroids are not an exclusion and are allowable.~* Pregnancy~* Inability to read or understand English

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Oral Viscous Budesonide (OVB) (Type: ACTIVE_COMPARATOR): Subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily.
- Active Fluticasone MDI (Type: ACTIVE_COMPARATOR): Subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB.

Based on this trial design, predict the completion outcome and termination type (if applicable).